Amylyx Pharmaceuticals Inc’s recently made public that its Co-Chief Executive Officer Klee Justin B. unloaded Company’s shares for reported $59429.0 on Sep 30 ’24. In the deal valued at $3.20 per share,18,589 shares were sold. As a result of this transaction, Klee Justin B. now holds 3,120,569 shares worth roughly $14.85 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Cohen Joshua B sold 18,589 shares, generating $59,414 in total proceeds. Upon selling the shares at $3.20, the Co-Chief Executive Officer now owns 3,220,569 shares.
Before that, Bedrosian Camille L sold 11,442 shares. Amylyx Pharmaceuticals Inc shares valued at $36,559 were divested by the Chief Medical Officer at a price of $3.20 per share. As a result of the transaction, Bedrosian Camille L now holds 143,801 shares, worth roughly $0.68 million.
BofA Securities upgraded its Amylyx Pharmaceuticals Inc [AMLX] rating to a Buy from a a Neutral in a research note published on October 23, 2024; the price target was increased to $10 from $4.20. A number of analysts have revised their coverage, including Mizuho’s analysts, who decreased its forecast for the stock in mid March from “a Buy” to “a Neutral”. Robert W. Baird also remained covering AMLX and has decreased its forecast on March 11, 2024 with a “Neutral” recommendation from previously “an Outperform” rating. Leerink Partners revised its rating on March 11, 2024. It rated AMLX as “a Market perform” which previously was an “an Outperform”.
Price Performance Review of AMLX
On Friday, Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] saw its stock fall -5.18% to $4.76. Over the last five days, the stock has lost -28.96%. Amylyx Pharmaceuticals Inc shares have fallen nearly -67.66% since the year began. Nevertheless, the stocks have fallen -63.61% over the past one year. While a 52-week high of $19.95 was reached on 02/29/24, a 52-week low of $1.58 was recorded on 06/17/24. SMA at 50 days reached $4.12, while 200 days put it at $4.39.
Levels Of Support And Resistance For AMLX Stock
The 24-hour chart illustrates a support level at 4.53, which if violated will result in even more drops to 4.30. On the upside, there is a resistance level at 5.03. A further resistance level may holdings at 5.30. The Relative Strength Index (RSI) on the 14-day chart is 45.23, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.64, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.97%. Stochastics %K at 15.64% indicates the stock is a buying.
How much short interest is there in Amylyx Pharmaceuticals Inc?
A steep rise in short interest was recorded in Amylyx Pharmaceuticals Inc stocks on 2024-10-31, growing by 9581.0 shares to a total of 1.29 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 1.28 million shares. There was a rise of 0.74%, which implies that there is a positive sentiment for the stock.
